杜他星
非那雄胺
医学
二氢睾酮
5α还原酶抑制剂
米诺地尔
睾酮(贴片)
泌尿科
脱发
药理学
不利影响
皮肤病科
内科学
雄激素
前列腺癌
前列腺
激素
癌症
作者
Tasleem Arif,Konchok Dorjay,Mohammad Adil,Marwa Sami
出处
期刊:Current Clinical Pharmacology
[Bentham Science]
日期:2017-03-15
卷期号:12 (1)
被引量:52
标识
DOI:10.2174/1574884712666170310111125
摘要
Background: Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-α-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-α-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia. In this review, after the pharmacology of dutasteride, the authors have discussed the status of dutasteride in androgenetic alopecia and have compared its efficacy with that of finasteride. Keywords: Androgenetic alopecia, dutasteride, finasteride, minoxidil, 5-α-reductase, testosterone, dihydrotestosterone.
科研通智能强力驱动
Strongly Powered by AbleSci AI